HIV
Conditions
Keywords
HIV, Anti-Retroviral agents, HIV-1, TMC114/r, Treatment naïve patients
Brief summary
The purpose of this study is to compare the efficacy, safety and tolerability of TMC114/r versus Kaletra (a combination pill of lopinavir and ritonavir, (lpv/rtv) in HIV-1 infected patients who have never been treated with anti-retroviral medications (referred to as treatment-naïve patients).
Detailed description
This is a randomized, controlled, open-label trial to investigate the antiviral activity, tolerability and safety of TMC114/r) versus lpv/rtv in treatment-naive HIV-1 infected patients. Six hundred sixty treatment-naïve HIV-1 infected patients will be randomized in a 1:1 ratio to either 800/100 mg of TMC114/r once daily, or a total daily dose of 800/200 mg of lpv/rtv. All patients will take TMC114/r or lpv/rtv in combination with an NRTI background of Truvada (a combination pill of tenofovir and emtricitabine, TDF/FTC). The trial will consist of a screening period of approximately 14 to 28 days and a 96-week treatment period, followed by a 4-week follow-up period. The anti HIV-1 therapy initiated at baseline cannot be changed until the end of the treatment period. After the end of the treatment period (maximum of 96 weeks), patients will be followed for an additional 4 weeks to follow-up on any adverse events or laboratory abnormalities until resolution. Patients who fail either virologically or due to intolerance from the TMC114/r or lpv/rtv therapy, as judged by the investigator, or who meet one of the withdrawal criteria will be withdrawn from the trial and may have the opportunity to participate in the rollover phase of the trial. The primary efficacy parameter is virologic response defined as a confirmed viral load \< 50 copies/mL at Week 48 the objective of this study is to establish non-inferiority of TMC114/r versus lpv/rtv in terms of virologic response at Week 48 using a non-inferiority margin of 12%. To test this hypothesis, a two-sided 95% confidence interval (CI) of the difference in response rate between TMC114/r and lpv/rtv will be derived: If the lower bound of the CI exceeds -12%, non-inferiority will be concluded. Patients will take oral doses for up to 96 weeks of either 800/100mg of TMC114/r 1x/day or 800/200mg of lpv/rtv once daily, each in combination with TDF/FTC. (The 400/100 mg 2x/day dose of lpv/rtv will be used where the 1x/day use of lpv/rtv is not approved).
Interventions
DRUGLPV/RTV
400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
DRUGTMC-114/RTV
two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
Sponsors
Tibotec Pharmaceuticals, Ireland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with documented HIV-1 infection * Screening plasma HIV-1 RNA \>= 5000 copies/mL * Patients qualify for treatment initiation based on the investigator's assessments and/or according to treatment guidelines * Patients who can comply with the protocol requirements * General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.
Exclusion criteria
* Presence of any currently active AIDS defining illness or receiving treatment for primary HIV infection * Life expectancy of less than 6 months * Previous or current use of antiretroviral medications (ARVs) for the treatment of HIV-infection or hepatitis B infection with anti-HIV activity * Female -patients who are pregnant or breast-feeding, or are of childbearing potential without use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period * -patients with a grade 3 or 4 laboratory abnormality as defined by DAIDS grading, or a calculated creatinine clearance (CLCr) \< 70 mL/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Confirmed Virologic Response defined as a Viral Load < 50 copies/mL at Week 48 | 48 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of safety, tolerability, and durability of efficacy over 96 weeks of treatment | 192 weeks |
Countries
Argentina, Australia, Austria, Belgium, Canada, Chile, Costa Rica, Denmark, France, Germany, Greece, Guatemala, Malaysia, Mexico, Panama, Puerto Rico, Russia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand, United Kingdom, United States
Outcome results
None listed